

Datum: 23.04.07

Selected publications:

see www.danubianbiobank.de (WP5) and attached extract of the Regensburg and collaborating center publications:

Prof. Gerd Schmitz, Institute for Clinical Chemistry, Regensburg

Porsch-Ozcurumez M, Hucke J, Westphal S, Hubacek JA, Schmitz G, Luley C.

A post-hoc analysis on the CD14 C(-260)T promoter polymorphism and coronary heart disease.

Physiol Res. 2006 Nov 6; [Epub ahead of print]

Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-Margoulis O, Schmitz-Madry A, Zahn A, Stremmel W, Schmitz G.

Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease.

J Mol Med. 2006 Dec;84(12):1055-1066. Epub 2006 Oct 21.

Schmitz G, Langmann T.

Metabolic learning in the intestine: adaptation to nutrition and luminal factors.

Horm Metab Res. 2006 Jul;38(7):452-4. Review.

Schmitz G, Schambeck CM.

Molecular defects in the ABCA1 pathway affect platelet function.

Pathophysiol Haemost Thromb. 2006;35(1-2):166-74. Review.

Binder M, Liebisch G, Langmann T, Schmitz G.

Metabolic profiling of glycerophospholipid synthesis in fibroblasts loaded with free cholesterol and modified low density lipoproteins.

J Biol Chem. 2006 Aug 4;281(31):21869-77.

Brasch F, Schimanski S, Muhlfeld C, Barlage S, Langmann T, Aslanidis C, Boettcher A, Dada A, Schroten H, Mildenerger E, Prueter E, Ballmann M, Ochs M, Johnen G, Griese M, Schmitz G.

Alteration of the pulmonary surfactant system in full-term infants with hereditary ABCA3 deficiency.

Am J Respir Crit Care Med. 2006 Sep 1;174(5):571-80.

Zhang B, Bottcher A, Imaizumi S, Noda K, Schmitz G, Saku K.

Relation between charge-based apolipoprotein B-containing lipoprotein subfractions and remnant-like particle cholesterol levels.

Atherosclerosis. 2007 Mar;191(1):153-61.

Schmitz G, Langmann T.

The lipid flux rheostat: implications of lipid trafficking pathways.

J Mol Med. 2006 Apr;84(4):262-5.

Werner T, Liebisch G, Grandl M, Schmitz G.

Evaluation of a high-content screening fluorescence-based assay analyzing the pharmacological modulation of lipid homeostasis in human macrophages.

Cytometry A. 2006 Mar;69(3):200-2.

Wolf Z, Orso E, Werner T, Boettcher A, Schmitz G.

A flow cytometric screening test for detergent-resistant surface antigens in monocytes.

Cytometry A. 2006 Mar;69(3):192-5.

Orso E, Werner T, Wolf Z, Bandulik S, Kramer W, Schmitz G.

Ezetimib influences the expression of raft-associated antigens in human monocytes.

Cytometry A. 2006 Mar;69(3):206-8.

Grandl M, Bared SM, Liebisch G, Werner T, Barlage S, Schmitz G.

E-LDL and Ox-LDL differentially regulate ceramide and cholesterol raft microdomains in human Macrophages.

Datum: 23.04.07

Cytometry A. 2006 Mar;69(3):189-91.

Muller D, Schmitz G, Theres K.
Blind homologous R2R3 Myb genes control the pattern of lateral meristem initiation in Arabidopsis.
Plant Cell. 2006 Mar;18(3):586-97.

Liebisch G, Binder M, Schifferer R, Langmann T, Schulz B, Schmitz G.
High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS).
Biochim Biophys Acta. 2006 Jan;1761(1):121-8.

Langmann T, Mauerer R, Schmitz G.
Human ATP-binding cassette transporter TaqMan low-density array: analysis of macrophage differentiation and foam cell formation.
Clin Chem. 2006 Feb;52(2):310-3.

Andrikovics H, Pongracz E, Kalina E, Szilvasi A, Aslanidis C, Schmitz G, Tordai A.
Decreased frequencies of ABCA1 polymorphisms R219K and V771M in Hungarian patients with cerebrovascular and cardiovascular diseases.
Cerebrovasc Dis. 2006;21(4):254-9.

Heimerl S, Moehle C, Zahn A, Boettcher A, Stremmel W, Langmann T, Schmitz G.
Alterations in intestinal fatty acid metabolism in inflammatory bowel disease.
Biochim Biophys Acta. 2006 Mar;1762(3):341-50.

Kubota H, Ishihara H, Langmann T, Schmitz G, Stieger B, Wieser HG, Yonekawa Y, Frei K.
Distribution and functional activity of P-glycoprotein and multidrug resistance-associated proteins in human brain microvascular endothelial cells in hippocampal sclerosis.
Epilepsy Res. 2006 Mar;68(3):213-28.

Schmitz G, Langmann T.
Pharmacogenomics of cholesterol-lowering therapy.
Vascul Pharmacol. 2006 Feb;44(2):75-89. Review.

Meiler C, Muhlbauer M, Johann M, Hartmann A, Schnabl B, Wodarz N, Schmitz G, Scholmerich J, Hellerbrand C. Different effects of a CD14 gene polymorphism on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection. World J Gastroenterol. 2005 Oct 14;11(38):6031-7.
Schmitz G, Langmann T. High-density lipoproteins and ATP-binding cassette transporters as targets for cardiovascular drug therapy. Curr Opin Investig Drugs. 2005 Sep;6(9):907-19.

Haiman M, Salvenmoser W, Scheiber K, Lingenhel A, Rudolph C, Schmitz G, Kronenberg F, Dieplinger H. Immunohistochemical localization of apolipoprotein A-IV in human kidney tissue. Kidney Int. 2005 Sep;68(3):1130-6.

Hafner C, Meyer S, Langmann T, Schmitz G, Bataille F, Hagen I, Becker B, Roesch A, Rogler G, Landthaler M, Vogt T.
Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healing in vitro.
World J Gastroenterol. 2005;11(26):4024-31.

Boger CA, Gotz A, Stubanus M, Banas B, Deinzer M, Kruger B, Holmer SR, Schmitz G, Riegger GA, Kramer BK.
C-reactive protein as predictor of death in end-stage diabetic nephropathy: Role of peripheral arterial disease.
Kidney Int. 2005;68(1):217-27.

Dulinska J, Gil D, Zagajewski J, Hartwich J, Bodzioch M, Dembinska-Kiec A, Langmann T, Schmitz G, Laidler P.
Different effect of beta-carotene on proliferation of prostate cancer cells.
Biochim Biophys Acta. 2005;1740(2):189-201.

Datum: 23.04.07

Langmann T, Liebisch G, Moehle C, Schifferer R, Dayoub R, Heiduczek S, Grandl M, Dada A, Schmitz G.

Gene expression profiling identifies retinoids as potent inducers of macrophage lipid efflux. *Biochim Biophys Acta*. 2005;1740(2):155-161.

Boger CA, Gotz AK, Kruger B, Hosl M, Schmitz G, Riegger GA, Kramer BK.

Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. *Eur J Med Res*. 2005;10(4):161-8.

Gotz AK, Boger CA, Hirschmann C, Schmitz G, Riegger GA, Kramer BK.

Effect of HMG-CoA-Reductase Inhibitors on Survival in Type 2 Diabetes Patients with End Stage Diabetic Nephropathy. *Eur J Med Res*. 2005;10(4):155-60.

Schmitz G, Langmann T.

Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. *Biochim Biophys Acta*. 2005 Jun 15;1735(1):1-19.

Boger CA, Fischereeder M, Deinzer M, Aslanidis C, Schmitz G, Stubanus M, Banas B, Kruger B, Riegger GA, Kramer BK.

RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. *Atherosclerosis*. 2005 Nov;183(1):121-9.

Bodzioch M, Dembinska-Kiec A, Hartwich J, Lapicka-Bodzioch K, Banas A, Polus A, Grzybowska J, Wybranska I, Dulinska J, Gil D, Laidler P, Placha W, Zawada M, Balana-Nowak A, Sacha T, Kiec-Wilk B, Skotnicki A, Moehle C, Langmann T, Schmitz G.

The microarray expression analysis identifies BAX as a mediator of beta-carotene effects on apoptosis.

Nutr Cancer. 2005;51(2):226-35.

Harangi M, Kaminski WE, Fleck M, Orso E, Zeher M, Kiss E, Szekanez Z, Zilahi E, Marienhagen J, Aslanidis C, Paragh G, Bolstad AI, Jonsson R, Schmitz G.

Homozygosity for the 168His variant of the minor histocompatibility antigen HA-1 is associated with reduced risk of primary Sjogren's syndrome.

Eur J Immunol. 2005;35(1):305-17.

Kramer W, Girbig F, Corsiero D, Pfenninger A, Frick W, Rhein M, Wendler W, Lottspeich F, Hochleitner EO, Orso E, Schmitz G.

Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor Ezetimibe in the enterocyte brush border membrane.

J Biol Chem. 2005;280(2):1306-20

Liebisch G, Lieser B, Rathenberg J, Drobnik W, Schmitz G.

High-throughput quantification of phosphatidylcholine and sphingomyelin by electrospray ionization tandem mass spectrometry coupled with isotope correction algorithm.

Biochim Biophys Acta. 2004;1686(1-2):108-17.

Bared SM, Buechler C, Boettcher A, Dayoub R, Siguener A, Grandl M, Rudolph C, Dada A, Schmitz G.

Association of ABCA1 with Syntaxin 13 and Flotillin-1 and Enhanced Phagocytosis in Tangier Cells. *Mol Biol Cell*. 2004 15(12):5399-407.

Ullrich H, Kleinjung T, Steffens T, Jacob P, Schmitz G, Strutz J.

Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis.

J Clin Apheresis. 2004;19(2):71-8.

Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch W, Baralle FE, Dallinga-Thie GM, Geisel J, Keller C, Menys VC, Schmitz G.

Screening for functional sequence variations and mutations in ABCA1.

Atherosclerosis. 2004;175(2):269-79.

Datum: 23.04.07

Buechler C, Bodzioch M, Bared SM, Siguener A, Boettcher A, Lapicka-Bodzioch K, Aslanidis C, Duong CQ, Grandl M, Langmann T, Dembinska-Kiec A, Schmitz G.
Expression pattern and raft association of NIPSNAP3 and NIPSNAP4, highly homologous proteins encoded by genes in close proximity to the ATP-binding cassette transporter A1.
Genomics. 2004;83(6):1116-24.

Duong CQ, Bared SM, Abu-Khader A, Buechler C, Schmitz A, Schmitz G.
Expression of the lysophospholipid receptor family and investigation of lysophospholipid-mediated responses in human macrophages.
Biochim Biophys Acta. 2004;1682(1-3):112-9.

Zanardo L, Stolz W, Schmitz G, Kaminski W, Vikkula M, Landthaler M, Vogt T.
Progressive hyperpigmentation and generalized lentiginosis without associated systemic symptoms: a rare hereditary pigmentation disorder in south-east Germany.
Acta Derm Venereol. 2004;84(1):57-60.

Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T.
Differential gene expression of eph receptors and ephrins in benign human tissues and cancers.
Clin Chem. 2004;50(3):490-9.

Lieser B, Liebisch G, Drobnik W, Schmitz G.
Quantification of sphingosine and sphinganine from crude lipid extracts by HPLC electrospray ionization tandem mass spectrometry.
J Lipid Res. 2003 Nov;44(11):2209-16.

Reichle A, Zaiss M, Rothe G, Schmitz G, Andreesen R.
Autologous tandem transplantation: almost complete reduction of neutropenic fever following the second transplantation by ex vivo expanded autologous myeloid postprogenitor cells.
Bone Marrow Transplant. 2003 Aug;32(3):299-305.

Hansson M, Ellis E, Hunt MC, Schmitz G, Babiker A.
Marked induction of sterol 27-hydroxylase activity and mRNA levels during differentiation of human cultured monocytes into macrophages.
Biochim Biophys Acta. 2003 Feb 17;1593(2-3):283-9.

Schmitz G, Drobnik W.
Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.
Clin Chem Lab Med. 2003 Apr;41(4):581-9. Review.

Drobnik W, Liebisch G, Audebert FX, Frohlich D, Gluck T, Vogel P, Rothe G, Schmitz G.
Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients.
J Lipid Res. 2003 Apr;44(4):754-61.

Langmann T, Mauerer R, Zahn A, Moehle C, Probst M, Stremmel W, Schmitz G.
Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues.
Clin Chem. 2003 Feb;49(2):230-8.

Christgau M, Aslanidis C, Felden A, Hiller KA, Schmitz G, Schmalz G.
Influence of interleukin-1 gene polymorphism on periodontal regeneration in intrabony defects.
J Periodontal Res. 2003 Feb;38(1):20-7.

Liebisch G, Drobnik W, Lieser B, Schmitz G.
High-throughput quantification of lysophosphatidylcholine by electrospray ionization tandem mass spectrometry.
Clin Chem. 2002 Dec;48(12):2217-24.

Kaminski WE, Klunemann HH, Ibach B, Aslanidis C, Klein HE, Schmitz G.
Identification of novel mutations in the NPC1 gene in German patients with Niemann-Pick C disease.
J Inher Metab Dis. 2002 Sep;25(5):385-9.

Buechler C, Bared SM, Aslanidis C, Ritter M, Drobnik W, Schmitz G.

Datum: 23.04.07

Molecular and functional interaction of the ATP-binding cassette transporter A1 with Fas-associated death domain protein.

J Biol Chem. 2002 Nov 1;277(44):41307-10.

Barlage S, Wimmer A, Pfeiffer A, Rothe G, Schmitz G.

MK-383 (tirofiban) induces a GPIIb/IIIa receptor conformation which differs from the resting and activated receptor.

Platelets. 2002 May;13(3):133-40.

Piehler A, Kaminski WE, Wenzel JJ, Langmann T, Schmitz G.

Molecular structure of a novel cholesterol-responsive A subclass ABC transporter, ABCA9.

Biochem Biophys Res Commun. 2002 Jul 12;295(2):408-16.

Schmitz G, Drobnik W.

ATP-binding cassette transporters in macrophages: promising drug targets for treatment of cardiovascular disease.

Curr Opin Investig Drugs. 2002 Jun;3(6):853-8.

Heimerl S, Langmann T, Moehle C, Mauerer R, Dean M, Beil FU, Von Bergmann K, Schmitz G.

Mutations in the human ATP-binding cassette transporters ABCG5 and ABCG8 in sitosterolemia.

Hum Mutat. 2002 Aug;20(2):151.

Harangi M, Aslanidis C, Paragh G, Schmitz G.

High-speed detection of the two common paraoxonase polymorphisms Leu55-->Met and Gln192-->Arg by real-time fluorescence PCR and melting curves.

Clin Chem Lab Med. 2002 Apr;40(4):337-40.

Drobnik W, Borsukova H, Bottcher A, Pfeiffer A, Liebisch G, Schutz GJ, Schindler H, Schmitz G.

Apo AI/ABCA1-Dependent and HDL3-Mediated Lipid Efflux from Compositionally Distinct Cholesterol-Based Microdomains.

Traffic. 2002 Apr;3(4):268-78.

Langmann T, Porsch-Ozcurumez M, Heimerl S, Probst M, Moehle C, Taher M, Borsukova H, Kielar D, Kaminski WE, Dittrich-Wengenroth E, Schmitz G.

Identification of sterol-independent regulatory elements in the human ATP-binding cassette transporter A1 promoter: role of Sp1/3, E-box binding factors, and an oncostatin M-responsive element.

J Biol Chem. 2002 Apr 26;277(17):14443-50.

Ullrich H, Jakob W, Frohlich D, Rothe G, Prasser C, Drobnik W, Taeger K, Meier-Hellmann A, Reinhart K, Zimmermann M, Schmitz G.

A new endotoxin adsorber: first clinical application.

Ther Apher. 2001 Oct;5(5):326-34.

Pfeiffer A, Bottcher A, Orso E, Kapinsky M, Nagy P, Bodnar A, Spreitzer I, Liebisch G, Drobnik W, Gempel K, Horn M, Holmer S, Hartung T, Multhoff G, Schutz G, Schindler H, Ulmer AJ, Heine H, Stelter F, Schutt C, Rothe G, Szollosi J, Damjanovich S, Schmitz G.

Lipopolysaccharide and ceramide docking to CD14 provokes ligand-specific receptor clustering in rafts.

Eur J Immunol. 2001 Nov;31(11):3153-64.

Diederich W, Orso E, Drobnik W, Schmitz G.

Apolipoprotein AI and HDL(3) inhibit spreading of primary human monocytes through a mechanism that involves cholesterol depletion and regulation of CDC42.

Atherosclerosis. 2001 Dec;159(2):313-24.

Kielar D, Dietmaier W, Langmann T, Aslanidis C, Probst M, Naruszewicz M, Schmitz G.

Rapid quantification of human ABCA1 mRNA in various cell types and tissues by real-time reverse transcription-PCR.

Clin Chem. 2001 Dec;47(12):2089-97.

Lapicka-Bodzioch K, Bodzioch M, Krull M, Kielar D, Probst M, Kiec B, Andrikovics H, Bottcher A, Hubacek J, Aslanidis C, Suttorp N, Schmitz G.

Datum: 23.04.07

Homogeneous assay based on 52 primer sets to scan for mutations of the ABCA1 gene and its application in genetic analysis of a new patient with familial high-density lipoprotein deficiency syndrome.

Biochim Biophys Acta. 2001 Jul 27;1537(1):42-8.

Buechler C, Ritter M, Duong CQ, Orso E, Kapinsky M, Schmitz G.
Adipophilin is a sensitive marker for lipid loading in human blood monocytes.
Biochim Biophys Acta. 2001 May 31;1532(1-2):97-104.

Schmitz G, Aslanidis C, Lackner KJ.
Pharmacogenomics: implications for laboratory medicine.
Clin Chim Acta. 2001 Jun;308(1-2):43-53. Review.
PMID: 11412816 [PubMed - indexed for MEDLINE]

Kapinsky M, Torzewski M, Buchler C, Duong CQ, Rothe G, Schmitz G.
Enzymatically degraded LDL preferentially binds to CD14(high) CD16(+) monocytes and induces foam cell formation mediated only in part by the class B scavenger-receptor CD36.
Arterioscler Thromb Vasc Biol. 2001 Jun;21(6):1004-10.

Barlage S, Frohlich D, Bottcher A, Jauhainen M, Muller HP, Noetzel F, Rothe G, Schutt C, Linke RP, Lackner KJ, Ehnholm C, Schmitz G.
ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response.
J Lipid Res. 2001 Feb;42(2):281-90.

Prof. Schäffler, Endocrinology, Regensburg

Geissler A, Fründ R, Schölmerich J, Feuerbach S, Zietz B. Alterations of cerebral metabolism in patients with diabetes mellitus studied by proton magnetic resonance spectroscopy. Exp Clin Endocr Diab 2003;111:421-427. IF: 1.438

Buettner R, Bollheimer CL, Zietz B, Drobnik W, Lackner KJ, Schmitz G, Schölmerich J, Palitzsch KD. Definition and characterization of relative hypo- and hyperleptinemia in a large Caucasian population. J Endocrinol 2002;175(3):745-756. IF: 2.834

Schäffler A, Barth N, Schmitz G, Zietz B, Palitzsch K-D, Schölmerich J. Frequency and significance of Pro12Ala and Pro115Gln polymorphism in gene for peroxisome proliferation-activated receptor-gamma regarding metabolic parameters in a Caucasian cohort. Endocrine 2001;14:369-373. IF: 1.609

Schäffler A, Buechler C, Müller-Ladner U, Herfarth H, Ehling A, Paul G, Schölmerich J, Zietz B. Identification of variables influencing resistin serum levels in patients with diabetes mellitus type 1 and type 2. Horm Metab Res 2004;36:702-707. IF: 1.591

Straub RH, Lehle K, Herfarth H, Weber M, Falk W, Preuner J, Schölmerich J. Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor. Eur J Endocrinol 2002;146:365-374. IF: 2.133

Zietz B, Barth N, Schölmerich J, Schmitz G, Schäffler A. Gly15Gly polymorphism within the human adipocyte-specific apM-1 gene but not Tyr111His polymorphism is associated with higher levels of cholesterol and LDL-cholesterol in Caucasian patients with type 2 diabetes. Exp Clin Endocr Diab 2001;109:320-325. IF: 1.406

Zietz B, Barth N, Spiegel D, Schmitz G, Schölmerich J, Schäffler A. Pro 2Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 (PPARgamma2) is associated with higher levels of total cholesterol and LDL-cholesterol in male caucasian type 2 diabetes patients. Exp Clin Endocr Diab 2002;110(2):60-66. IF: 1.617

Zietz B, Buechler C, Drobnik W, Herfarth H, Schölmerich J, Schäffler A. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels. Endocr Res 2004;30:443-453. IF: 0.662

Datum: 23.04.07

Prof. Hengstenberg, Cardiology, Regensburg

Bässler A, Fischer M, Huf V, Mell S, Hengstenberg C, Mayer B, Holmer S, Riegger G, Schunkert H. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. *Int J Cardiol* 2005;101(2):293-298. IF: 2.095

Bezzina CR, Verkerk AO, Busjahn A, Jeron A, Erdmann J, Koopmann TT, Bhuiyan ZA, Wilders R, Mannens MM, Tan HL, Luft FC, Schunkert H, Wilde AA. A common polymorphism in KCNH2 (HERG) hastens cardiac repolarization. *Cardiovasc Res* 2003;59(1):27-36. IF: 4.692

Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, Döring A, Broeckel U, Riegger G, Schunkert H. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. *Eur Heart J* 2003;24(4):320-328. IF: 6.131

Fischer M, Baessler A, Holmer SR, Muscholl M, Broeckel U, Luchner A, Hense HW, Döring A, Riegger G, Schunkert H. Epidemiology of left ventricular systolic dysfunction in the general population of Germany: results of an echocardiographic study of a large population-based sample. *Z Kardiol* 2003;92(4):294-302. IF: 0.764

Fischer M, Bässler A, Hengstenberg C, Holmer S, Mayer B, Löwel H, Riegger GA, Klein G, Schunkert H. ACE-Inhibition bei Myokardinfarktpatienten mit eingeschränkter Ventrikelfunktion: Umsetzung von Therapiestandards in Bevölkerungsstichproben. *Z Kardiol* 2001;90(2):104-110. IF: 0.874

Fischer M, Broeckel U, Holmer S, Baessler A, Hengstenberg C, Mayer B, Erdmann J, Klein G, Riegger G, Jacob HJ, Schunkert H. Distinct heritable patterns of angiographic coronary artery disease in families with myocardial infarction. *Circulation* 2005;111(7):855-862. IF: 12.563

Fischer M, Lieb W, Marold D, Berthold M, Baessler A, Löwel H, Hense HW, Hengstenberg C, Holmer S, Schunkert H, Erdmann J. Lack of association of a 9 bp insertion/deletion polymorphism within the bradykinin 2 receptor gene with myocardial infarction. *Clin Sci (Lond)* 2004;107(5):505-511. IF: 2.117

Hengstenberg C, Bröckel U, Holmer S, Martin LJ, Comuzzie AG, Blangero J, Nurnberg P, Reis A, Riegger GA, Jacob HJ, Schunkert H. A comprehensive linkage analysis for myocardial infarction and its related risk factors. *Nat Genet* 2002;30(2):210-214. IF: 29.600

Hengstenberg C, Schunkert H, Mayer B, Döring A, Löwel H, Hense HW, Fischer M, Riegger GA, Holmer S. Association between a polymorphism in the G protein beta3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction. *Cardiovasc Res* 2001;49(4):820-827. IF: 3.789

Holmer SR, Bickeböller H, Hengstenberg C, Rohlmann F, Engel S, Löwel H, Mayer B, Erdmann J, Baier C, Klein G, Riegger GA, Schunkert H. Angiotensin converting enzyme gene polymorphism and myocardial infarction a large association and linkage study. *Int J Biochem Cell Biol* 2003;35(6):955-962. IF: 3.044

Holmer SR, Hengstenberg C, Kraft HG, Mayer B, Pöll M, Kürzinger S, Fischer M, Löwel H, Klein G, Riegger GA, Schunkert H. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. *Circulation* 2003;107(5):696-701. IF: 10.255

Jeron A, Hengstenberg C, Engel S, Löwel H, Riegger GA, Schunkert H, Holmer S. The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction. *Eur Heart J* 2001;22(8):663-668. IF: 3.840

Jeron A, Hengstenberg C, Holmer S, Wollnik B, Riegger GA, Schunkert H, Erdmann J. KCNJ11 polymorphisms and sudden cardiac death in patients with acute myocardial infarction. *J Mol Cell Cardiol* 2004;36(2):287-293. IF: 4.954

Kuch B, Gneiting B, Döring A, Muscholl MW, Bröckel U, Schunkert H, Hense HW. Indexation of left ventricular mass in adults with a novel approximation for fat-free mass. *J Hypertens* 2001;19(1):135-142. IF: 3.640

Lieb W, Pavlik R, Erdmann J, Mayer B, Holmer SR, Fischer M, Baessler A, Hengstenberg C, Loewel H, Doering A, Riegger GA, Schunkert H. No association of interleukin-6 gene polymorphism (-174

Datum: 23.04.07

G/C) with myocardial infarction or traditional cardiovascular risk factors. *Int J Cardiol* 2004;97(2):205-212. IF: 1.892

Luchner A, Bröckel U, Muscholl M, Hense HW, Döring A, Riegger GA, Schunkert H. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. *Cardiovasc Res* 2002;53(3):720-727. IF: 4.552

Luchner A, Hengstenberg C, Lowel H, Buchner S, Schunkert H, Riegger GA, Holmer S. NT-ProBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. *J Card Fail* 2005;11(5 Suppl):S21-S27. IF: 2.879

Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. *Hypertension* 2005;46(1):118-123. IF: 5.342

Luchner A, Hengstenberg C, Löwel H, Trawinski J, Baumann M, Riegger GA, Schunkert H, Holmer S. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. *Hypertension* 2002;39(1):99-104. IF: 5.364

Lukowicz TV, Fischer M, Hense HW, Doring A, Stritzke J, Riegger G, Schunkert H, Luchner A. BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy. *Eur J Heart Fail* 2005;7(4):525-531. IF: 2.796

Mayer B, Lieb W, Götz A, König IR, Aherrahrou Z, Thiemig A, Holmer S, Hengstenberg C, Doering A, Loewel H, Hense HW, Schunkert H, Erdmann J. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. *Hypertension* 2005;46(4):766-771. IF: 5.342

Sedlacek K, Fischer M, Erdmann J, Hengstenberg C, Holmer S, Kürzinger S, Muscholl M, Luchner A, Riegger GA, Hense HW, Schunkert H. Relation of the G protein beta3-subunit polymorphism with left ventricle structure and function. *Hypertension* 2002;40(2):162-167. IF: 5.364

Andreas Luchner, Kardiologie, Regensburg
klin.-epidemiologischen Kollektiven KORA-B und MONICA-S3 (zusammen mit GSF).

Schunkert H, Hense HW, Muscholl M, Luchner A, Riegger GAJ. Association of angiotensin converting enzyme activity and arterial blood pressure in a population-based sample. *J Hypertension* 1996;14:571-575

Schunkert H, Hense HW, Muscholl M, Luchner A, Kürzinger S, Danser AH, Riegger GA. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. *Heart* 1997;77(1):24-31

Schunkert H, Hense HW, Bröckel U, Luchner A, Muscholl M, Holmer S, Danser AHJ, Mayer B, Riegger GAJ. Differential effects of antihypertensive drugs on neurohumoral activation: insights from a population-based sample. *J Internal Med* 1998;244:109-119

Luchner A, Burnett JCJr, Jougasaki M, Hense HW, Riegger GAJ, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. *JACC* 1998;32:1839-44

Luchner A, Burnett JCJr, Jougasaki M, Hense HW, Heid IM, Muders F, Riegger GAJ, Schunkert H. Evaluation of Brain Natriuretic Peptide (BNP) as Marker of Left Ventricular Dysfunction and Hypertrophy in the Population. *J Hypertension* 2000;18(8):1121-1128

Luchner A, C Hengstenberg, H Löwel, J Trawinski, M Baumann, GAJ Riegger, H Schunkert, S Holmer. Plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients after myocardial infarction: a biochemical marker of cardio-renal function. *Hypertension* 2002; 39(1):99-104

McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrand P, Dargie HJ. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. *Eur J Heart Fail.* 2004;6(3):269-73.

Datum: 23.04.07

Lukowicz T, Fischer M, Hense HW, Doering A, Stritzke J, Riegger GA, Schunker H, Luchner A. BNP as a marker of diastolic dysfunction in the general population: Importance of left ventricular hypertrophy. *Eur J Heart Failure* 2005;7(4):525-531

Luchner A, C Hengstenberg, H Löwel, GAJ Riegger, H Schunkert, S Holmer. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal Pro-BNP. *Hypertension* 2005; 46:1-6

Luchner A, C Hengstenberg, H Löwel, S Buchner, H Schunkert, GAJ Riegger, S Holmer. NT-proBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. *J Cardiac Failure* 2005;11(5, Suppl.):S21-27

Prof. Krämer, Nephrology, Regensburg

Böger CA, Fischereeder M, Deinzer M, Aslanidis C, Schmitz G, Stubanus M, Banas B, Kruger B, Riegger GA, Krämer BK. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. *Atherosclerosis* 2005;183(1):121-129. IF: 3.796

Böger CA, Götz A, Stubanus M, Banas B, Deinzer M, Kruger B, Holmer SR, Schmitz G, Riegger GA, Krämer BK. C-reactive protein as predictor of death in end-stage diabetic nephropathy: role of peripheral arterial disease. *Kidney Int* 2005;68(1):217-227. IF: 4.790

Böger CA, Götz AK, Kruger B, Hösl M, Schmitz G, Riegger GA, Krämer BK. Effect of genetic variation on therapy with angiotensin converting enzyme inhibitors or angiotensin receptor blockers in dialysis patients. *Eur J Med Res* 2005;20;10(4):161-168. IF: 1.250

Fischereeder M, Luckow B, Hoher B, Wuthrich RP, Rothenpieler U, Schneeberger H, Panzer U, Stahl RA, Hauser IA, Budde K, Neumayer H, Krämer BK, Land W, Schlondorff D. CC chemokine receptor 5 and renal-transplant survival. *Lancet* 2001;357(9270):1758-1761. IF: 10.232

Fischereeder M, Schneeberger H, Lohse P, Krämer BK, Schlondorff D, Land W. Increased rate of renal transplant failure in patients with the G20210A mutation of the prothrombin gene. *Am J Kidney Dis* 2001;38(5):1061-1064. IF: 3.646

Götz AK, Böger CA, Hirschmann C, Schmitz G, Riegger GA, Krämer BK. Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy. *Eur J Med Res* 2005;20;10(4):155-160. IF: 1.250

Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuno J, Kohler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Muhlbacher F, Rivero M, Arias M. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results. *Nephrol Dial Transplant* 2005;20(5):968-973. IF: 2.840

Krüger B, Schröppel B, Ashkan R, Marder B, Zülke C, Murphy B, Krämer BK, Fischereeder M. A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. *J Am Soc Nephrol* 2002;13(10):2585-2589. IF: 6.337

Panzer U, Schneider A, Steinmetz OM, Wenzel U, Barth P, Reinking R, Becker JU, Harendza S, Zahner G, Fischereeder M, Krämer BK, Schlondorff D, Ostendorf T, Floege J, Helmchen U, Stahl RA. The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. *Kidney Int* 2005;67(1):75-81. IF: 4.790

Schröppel B, Fischereeder M, Ashkar R, Lin M, Krämer BK, Mardera B, Schiano T, Murphy B. The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. *Am J Transplant* 2002;2(7):640-645. IF: -

Schröppel B, Fischereeder M, Lin M, Marder B, Schiano T, Krämer BK, Murphy B. Analysis of gene polymorphisms in the regulatory region of MCP-1, RANTES, and CCR5 in liver transplant recipients. *J Clin Immunol* 2002;22(6):381-385. IF: 3.442

Datum: 23.04.07

Vitko S, Klinger M, Salmela K, Wlodarczyk Z, Tyden G, Senatorski G, Ostrowski M, Fauchald P, Kokot F, Stefoni S, Perner F, Claesson K, Castagneto M, Heemann U, Carmellini M, Squifflet JP, Weber M, Segoloni G, Backman L, Sperschneider H, Krämer BK. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. *Transplantation* 2005;80:1734-1741. IF: 3.568

Prof. Bornstein, Dr. Schwarz, Technische Universität Dresden

Hampl M, Chang-Claude J, Schwarz P, Saeger HD, Schackert HK: [Molecular genetics of hereditary breast carcinoma]. *Zentralbl Chir* 122:67-73, 1997

Hampl M, Plaschke J, Burgemeister R, Schwarz P, Saeger HD, Schackert HK: [Sequence analysis of BRCA1 gene in young breast cancer patients and/or positive family history]. *Langenbecks Arch Chir Suppl Kongressbd* 115:267-272, 1998

Hampl M, Hampl JA, Schwarz P, Frank S, Hahn M, Schackert G, Saeger HD, Schackert HK: Accumulation of genetic alterations in brain metastases of sporadic breast carcinomas is associated with reduced survival after metastasis. *Invasion Metastasis* 18:81-95, 1998

Horikawa Y, Oda N, Cox N.J, Li X, Orho-Melander M, Hara M, Hinokio Y, Lindner T, Mashima H, Schwarz P.E.H, Del Bosque-Plata L, Horikawa Y, Oda Y, Yoshiuchi I, Colilla S, Polonsky K, Wei S, Concannon P, Iwasaki K, Schulze J, Beier L, Bogardus C, Groop L, Boerwinkle E, Hanis C.L, G.I. Bell. Genetic variation in the calpain 10 gene (CAPN10) is associated with type 2 diabetes mellitus, *Nature Genetics*, 2000. 26(1): p. 163-175

del Bosque-Plata L, Lin J, Horikawa Y, Schwarz PE, Cox NJ, Iwasaki N, Ogata M, Iwamoto Y, German MS, Bell GI: Mutations in the coding region of the neurogenin 3 gene (NEUROG3) are not a common cause of maturity-onset diabetes of the young in Japanese subjects. *Diabetes* 50:694-696., 2001

P.E.H. Schwarz, T. Selisko, H. Rietzsch, T. Lindner, J. Schulze: Ist Diabetes erkennbar? Genetische Untersuchungen aus Sachsen. *Sächsisches Ärzteblatt* (2001) 11(09):36-41

T. Selisko, J. Včelák, B. Bendlová, J. Graessler, P. E. H. Schwarz, J. Schulze: Mutations and intronic variants in the HNF-1beta gene in a group of German and Czech Caucasians with diabetes mellitus type 2 and progressive diabetic nephropathy, *Exp Clin Endocrinol Diabetes*, 2002. 110(3): p. 145-7.

Ehrmann D, Schwarz P.E.H, Cox N.J, Horikawa Y, Bogardus C, Groop L, Boerwinkle E, Hanis C.L, Polonsky K, G.I. Bell., (2002). "Relationship of calpain-10 genotype to pheno-typic features of polycystic ovary syndrome." *J Clin Endocrinol Metab* 87(4): 1669-73.

Gorgens, H., P. Schwarz, Schulze, J., Schackert, H. K., (2003). "LightCycler assay in the analysis of haplotypes of the type 2 diabetes susceptibility gene CAPN10." *Clin Chem* 49(8): 1405-8.

Naoko Iwasaki, Nancy J. Cox, Yan-Qing Wang, Peter E.H. Schwarz, Graeme I. Bell, Masashi Honda, Mitsuo Imura, Makiko Ogata, Masayuki Saito, Naoyuki Kamatani, and Yasuhiko Iwamoto; Mapping Genes Influencing Type 2 Diabetes Risk and Body Mass Index in Japanese, (2003). "Mapping genes influencing type 2 diabetes risk and BMI in Japanese subjects." *Diabetes* 52(1): 209-13.

P. Schwarz, J. Schwarz, S. Fischer, J. Schulze.; Gründung der "Arbeitsgemeinschaft Prävention des Typ-2-Diabetes" der DDG auf dem diesjährigen Kongress der Deutschen Diabetes Gesellschaft in Bremen. *Diabetes und Stoffwechsel*, 2003. 4(7): p. 178-185.

Weedon MN, Schwarz PE, Horikawa Y, Iwasaki N, Illig T, Holle R, Rathmann W, Selisko T, Schulze J, Owen KR, Evans J, Del Bosque-Plata L, Hitman G, Walker M, Levy JC, Sampson M, Bell GI, McCarthy MI, Hattersley AT, Frayling TM: Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. *Am J Hum Genet*, 2003. 73(6): p. 1208-12.

S. Fischer, U. Julius, M. Hanefeld K. Fückler, J. Gräßler, W. Towers U. Schwanebeck, J. Schulze, P. Schwarz.; Das Vorkommen von Allel 1.1 im SNP 44 ist im Stadium des Typ-2 Diabetes mit erhöhten Insulin- und C-Peptid-Werten assoziiert; *Diabetes und Stoffwechsel*, 2004. 13(1): p. 3-9.

Datum: 23.04.07

Schwarz PEH Prävention des Diabetes mellitus Typ 2, Lebensstiländerung und medikamentöse Intervention. Notfall & Hausarztmedizin, 2005, 31:19-26

Schwarz PE., Report from the Congress of the American Diabetes Association (ADA): Orlando 2005 - 65th Annual Scientific Sessions in San Diego, CA, USA, June 10th-14th 2005, Exp Clin Endocrinol Diabetes. 2005 Sep;113(8):475-9.

Schwarz P. Risikoerkennung zur Prävention des Diabetes mellitus Typ2. Diabetes aktuell für die Hausarztpraxis, 2005, 1:5-8

Schwarz, P., Targeted diabetes prevention in high risk groups: pro. Dtsch Med Wochenschr, 2005. 130(17): p. 1103.

Valensi P, Schwarz PEH, Hall M, Felton AM, Maldonato A, Mathieu C. Prediabetes essential action: a European perspective. Diabetes Metab 2005;31(6):606-20.

Schwarz P, Schwarz J, Bornstein S, Schulze J: Prevention of type 2 diabetes: what challenges do we have to address. Journal of Public Health, 2005. 2(13): p. 296-303.

Schwarz, P., Pharmako-Prävention des Diabetes mellitus Typ 2 PERFUSION, 2005. 3(3): p. 23-26.

Schutte AE, O'Dea K, Schwarz PE: Could statistical adjustments for age mask the insulin-blood pressure relationship? Diabetes Res Clin Pract 72:104-107, 2006

Peter E.H.Schwarz und Stefan R.Bornstein, Genetik des Gestationsdiabetes, Diabetes aktuell 2006;4 (1):25-27

Schwarz P, Gruhl U, Hoffmann R, Bornstein S: Prävention des Diabetes mellitus: Risiko-Erkennung – Intervention – Weiterbetreuung. Kompendium Diabetes 1:15-19, 2006

Trajkovski M, Mziaut H, Schwarz PE, Solimena M: Genes of type 2 diabetes in Beta cells. Endocrinol Metab Clin North Am, 2006. 35(2): p. 357-69.

Schwarz PE, Bornstein SR. Related Articles, Pre-diabetes and metabolic syndrome in Germans. Horm Metab Res. 2006 May;38(5):359.

P. Schwarz, U. Gruhl, R. Hoffmann, R. Landgraf; Prävention des Diabetes mellitus in Deutschland – Ein praktischer Leitfaden zur Implementierung von Präventions-Programmen, Diabetes aktuell 2006;4 (2):37-42

K. Kaline, P. E. Schwarz; Frühzeitige Intervention bei Übergewicht – Gewichtsreduktion als wichtigste Präventionsmaßnahme; Diabetes aktuell 2006;4 (2):53-57

Schuppenies A, Schwarz P, Bornstein SR. Seasonal affective disorder and HPA axis disturbance. Horm Metab Res. 2006 Jun;38(6):434.

Walter M, Rädcl M, Wittig M, Wolf W, Schütte S, Bornstein S, Schwarz P: Der Betriebsarzt im Dienst von Früherkennung und Prävention. Diabetes aktuell 2006;4 (3):87–92

Schwarz PE, Govindarajalu S, Towers W, Schwanebeck U, Fischer S, Vasseur F, Bornstein SR, Schulze J. Haplotypes in the promoter region of the ADIPOQ gene are associated with increased diabetes risk in a German Caucasian population. Horm Metab Res. 2006 Jul;38(7):447-51.

Schwarz PE, Schwarz J, Bornstein SR, Schulze J. Diabetes prevention--from physiology to implementation.Horm Metab Res. 2006 Jul;38(7):460-4.

Schwarz PE, Towers GW, Fischer S, Govindarajalu S, Schulze J, Bornstein SR, Hanefeld M, Vasseur F.; Hypoadiponectinemia is associated with progression toward type 2 diabetes and genetic variation in the ADIPOQ gene promoter. Diabetes Care. 2006 Jul;29(7):1645-50.

Hanefeld M, Ceriello A, Schwarz PE, Bornstein SR. The metabolic syndrome--a postprandial disease? Horm Metab Res. 2006 Jul;38(7):435-6.

Datum: 23.04.07

Tsuchiya T, Schwarz PE, Bosque-Plata LD, Geoffrey Hayes M, Dina C, Froguel P, Wayne Towers G, Fischer S, Temelkova-Kurktschiev T, Rietzsch H, Graessler J, Vcelak J, Palyzova D, Selisko T, Bendlova B, Schulze J, Julius U, Hanefeld M, Weedon MN, Evans JC, Frayling TM, Hattersley AT, Orho-Melander M, Groop L, Malecki MT, Hansen T, Pedersen O, Fingerlin TE, Boehnke M, Hanis CL, Cox NJ, Bell GI. Association of the calpain-10 gene with type 2 diabetes in Europeans: results of pooled and meta-analyses. *Mol Genet Metab.* 2006 Sep-Oct;89(1-2):174-84.

Schwarz PE, Schuppenies A, Gruhl U, Hoffmann R, Bornstein SR, Schulze J, Landgraf R. Prevention of type 2 diabetes in Germany. Ideas-evidence-implementation. *Med Klin (Munich).* 2006 Sep 15;101(9):730-6. German.

Schuppenies A, Jacobey H, Bornstein S, Schwarz PE; FINDRISK - Development of a questionnaire to estimate the risk of diabetes; *ERNAHRUNGS-UMSCHAU* 53 (10): 386, Oct 2006

Schwarz PE, Bornstein SR, Hanefeld M.; Elevated fasting glucose levels predicts IGT and diabetes also in middle-age subjects. *Diabetes Res Clin Pract.* 2006 Nov 6

Reimann M, Schutte AE, Huisman HW, Schutte R, van Rooyen JM, Malan L, Malan NT, Schwarz PE: Ethnic differences in C-peptide secretion but not in non-esterified fatty acid metabolism in premenopausal women with and without abdominal obesity. *Diabetes Res Clin Pract.* 2006, Nov 10

Schwarz PE.; Congress report from the american diabetes association, *Exp Clin Endocrinol Diabetes.* 2006 Nov;114 (10):605-10.

Kruger HS, Rautenbach PH, Venter CS, Wright HH, Schwarz PE: An inverse association between calcium and adiposity in women with high fat and calcium intakes. *Ethn Dis* 17:6-13, 2007

Schwarz PE, Gruhl U, Schuppenies A, Schulze J, Bornstein SR: Prevention of diabetes mellitus: The future of German diabetology. *Hamostaseologie* 27:13-21, 2007

Schwarz P, Schwarz J, Schuppenies A, Bornstein S, Schulze J.: Development of a Diabetes Prevention Management Program for Clinical Practice accepted for publication in *Public Health Report*

Dr. Küneman, Neurology, Regensburg

Klunemann HH, Hulla K, Gurtler K, Marienhagen J. [A bavarian kindred with Parkinson disease, dementia and pyramidal tract signs.] *Psychiatr Prax.* 2007 Jan;34(1 Suppl):122-3. German.

Bader C, Koch H, Orso E, Ibach B, Klunemann HH. [Family History of Dementia in 1st-Degree Relatives of Patients with Dementia Onset before Age 70 Years.] *Psychiatr Prax.* 2007 Jan;34(1 Suppl):114-6. German.

Klarner B, Klunemann HH, Lurding R, Aslanidis C, Rupprecht R. Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations. *J Inherit Metab Dis.* 2007 Feb;30(1):60-7. Epub 2006 Dec 11.

Klunemann HH, Fronhofer W, Werner-Fuchtenbusch D, Grasbon-Frodl E, Kloiber S, Wurster HW, St George-Hyslop PH, Rogaeva E. Characterization of the kindred of Alois Alzheimer's patient with plaque-only dementia. *Alzheimer Dis Assoc Disord.* 2006 Oct-Dec;20(4):291-4.

Prof. Meitinger, GSF Neuherberg, Munich

Kemlink D, Polo O, Montagna P, Provini F, Stiasny-Kolster K, Oertel W, de Weerd A, Nevsimalova S, Sonka K, Hogl B, Frauscher B, Poewe W, Trenkwalder C, Pramstaller PP, Ferini-Strambi L, Zucconi M, Konofal E, Arnulf I, Hadjigeorgiou GM, Happe S, Klein C, Hiller A, Lichtner P, Meitinger T, Muller-Myshok B, Winkelmann J. Family-based association study of the restless legs syndrome loci 2 and 3 in a European population. *Mov Disord.* 2007 Jan 15;22(2):207-12.

Fisher SA, Rivera A, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Rudolph G, Weber BH. Case-control genetic association study of fibulin-6 (FBLN6 or HMCN1) variants in age-related macular degeneration (AMD). *Hum Mutat.* 2007 Jan 10;28(4):406-413

Datum: 23.04.07

Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. *Hum Mol Genet.* 2005 Nov 1;14(21):3227-36.

Stogmann E, Lichtner P, Baumgartner C, Bonelli S, Assem-Hilger E, Leutmezer F, Schmied M, Hotzy C, Strom TM, Meitinger T, Zimprich F, Zimprich A. Idiopathic generalized epilepsy phenotypes associated with different EFHC1 mutations. *Neurology.* 2006 Dec 12;67(11):2029-31.

Stogmann E, Lichtner P, Baumgartner C, Schmied M, Hotzy C, Asmus F, Leutmezer F, Bonelli S, Assem-Hilger E, Vass K, Hatala K, Strom TM, Meitinger T, Zimprich F, Zimprich A. Mutations in the CLCN2 gene are a rare cause of idiopathic generalized epilepsy syndromes. *Neurogenetics.* 2006 Nov;7(4):265-8.

Hartig MB, Hortnagel K, Garavaglia B, Zorzi G, Kmiec T, Klopstock T, Rostasy K, Svetel M, Kostic VS, Schuelke M, Botz E, Weindl A, Novakovic I, Nardocci N, Prokisch H, Meitinger T. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. *Ann Neurol.* 2006 Feb;59(2):248-56.

Biskup S, Mueller JC, Sharma M, Lichtner P, Zimprich A, Berg D, Wullner U, Illig T, Meitinger T, Gasser T. Common variants of LRRK2 are not associated with sporadic Parkinson's disease. *Ann Neurol.* 2005 Dec;58(6):905-8.

Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Muller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron.* 2004 Nov 18;44(4):601-7.

Prof. H. Stockinger, Molecular Immunology, Vienna

Moertelmaier, M., M. Brameshuber, M. Linimeier, H. Stockinger, and G. J. Schütz. 2005. TOCCSL: Thinning Out Clusters while Conserving Stoichiometry of Labeling. *Appl. Phys. Lett.* 87: 263903/1-263903/3. Selected for: *Virtual Journal of Biological Physics Research.* 11: Jan 1, 2006.

Madl, J., S. Rhode, H. Stangl, H. Stockinger, P. Hinterdorfer, G. J. Schütz, and G. Kada. 2006. A combined optical and atomic force microscope for live cell investigations. *Ultramicroscopy* 106:645.

Wieser, S., M. Moertelmaier, E. Fürtbauer, H. Stockinger, and G. J. Schütz. 2007. (Un)confined diffusion of CD59 in the plasma membrane determined by high-resolution single molecule microscopy. *Biophys. J.*:In press.

Drbal, K., M. Moertelmaier, C. Holzhauser, A. Muhammad, E. Fürtbauer, S. Howorka, M. Hinterberger, H. Stockinger*, and G. J. Schütz. 2007. Single molecule microscopy reveals heterogeneous dynamics of lipid raft components upon T cell receptor engagement. *Int. Immunol.*:In press. *Corresponding author.

Groyer, E., A. Nicoletti, H. Ait-Oufella, J. Khallou-Laschet, A. Varthaman, A. T. Gaston, O. Thauat, S. V. Kaveri, R. Blatny, H. Stockinger, Z. Mallad, and G. Caligiuri. 2007. Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T cells. *J. Am. Coll. Cardiol.*: In press.

Patent application: New Method for detection of Protein interactions in living cells by patterned surfaces.

Inventors: Michaela Schwarzenbacher (Uni.Linz), Gerhard J. Schütz (Uni.Linz), Alois Sonnleitner (UAR); Hannes Stockinger (Med Uni Wien), Martin Kaltenbrunner (Uni.Linz. Diplomand)

Prof. C. Mannhalter, Clinical Chemistry, Vienna

Lalouschek W, Endler G, Schillinger M, Hsieh K, Lang W, Cheng S, Bauer P, Wagner O, Mannhalter C. Candidate genetic risk factors of stroke: results of a multilocus genotyping assay. *Clin Chem.* 2007 Apr;53(4):600-5.

Datum: 23.04.07

Ferrari J, Rieger S, Endler G, Greisenegger S, Funk M, Scholze T, Lang W, Lalouschek W, Mannhalter C. The Thr715Pro polymorphism of the P-selectin gene is not associated with ischemic stroke risk. *Stroke*. 2007 Feb;38(2):395-7

Funk M, Endler G, Lalouschek W, Hsieh K, Schillinger M, Lang W, Mannhalter C. Factor VII gene haplotypes and risk of ischemic stroke. *Clin Chem*. 2006 Jun;52(6):1190-2

Hsieh K, Lalouschek W, Schillinger M, Endler G, Reisinger M, Janisiw M, Lang W, Cheng S, Wagner O, Mannhalter C. Impact of alphaENaC polymorphisms on the risk of ischemic cerebrovascular events: a multicenter case-control study. *Clin Chem*. 2005 Jun;51(6):952-6

Hsieh K, Funk M, Schillinger M, Endler G, Janisiw M, Reisinger M, Unger P, Greisenegger S, Lang W, Lalouschek W, Mannhalter C. Vienna Stroke Registry. Impact of the platelet glycoprotein Ib alpha Kozak polymorphism on the risk of ischemic cerebrovascular events: a case-control study. *Blood Coagul Fibrinolysis*. 2004 Sep;15(6):469-73

Greisenegger S, Endler G, Hsieh K, Tentschert S, Mannhalter C, Lalouschek W. Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? *Stroke*. 2004 Jul;35(7):1688-91

Prof Andreas Koranyi, Transdanubian Genbank, DRC Ltd, Hungary

Drug Research Centre (DRC) Ltd was founded in 1997 as a privately owned Hungarian Clinical Research Company for providing services to the healthcare and allied pharmaceutical biotechnological industries. These services include Phase I-IV Clinical Trials and their managements according to the ICH Tripartite Guideline on GCP. The DRC organization is complete with Phase I units, Biochemical- and Pharmacegenomics Laboratories, Out- Patient Clinics at the field of cardiology, diabetes and osteoposis and a SMO (Site Management Organization) with a large network of GP's.

Csep K, Vitay M, Dudutz G, Rosivall L, Koranyi L. [Relationship of FABP2-A54T polymorphism and the metabolic syndrome in the Romanian Maros county.] *Orv Hetil*. 2007 Apr 1;148(13):597-602.

Prof. F. Keller, Nephrology, University Ulm

Aymanns C, Voehringer M, Rasche FM, Keller F. Effects of sirolimus on proteinuria and renal function in focal segmental glomerulonephritis. *Int J Clin Pharmacol Ther*. 2006 Dec;44(12):675-6. No abstract available.

Rasche FM, Keller F, von Muller L, Sailer LK, Karges W, Czock D. Mycophenolic acid therapy after cyclophosphamide pulses in progressive IgA nephropathy. *J Nephrol*. 2006 Jul-Aug;19(4):465-72.

Keller F, Ludwig U, Czock D. Nephro-pharmacology. *Int J Clin Pharmacol Ther*. 2006 Aug;44(8):343.

Kielstein JT, Czock D, Schopke T, Hafer C, Bode-Boger SM, Kuse E, Keller F, Fliser D. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. *Crit Care Med*. 2006 Jan;34(1):51-6.

Czock D, Haussler U, Aymanns C, Keller F. *Dtsch Med Wochenschr*. 2005 Nov 11;130(45):2579-84; quiz 2585-6.

Rasche FM, Keller F, Czock D. [Chemotherapy in patients with renal failure, dialysis and after transplantation] *Dtsch Med Wochenschr*. 2005 Sep 9;130(36):2043-6. Review. German.

Kielstein JT, Stadler M, Czock D, Keller F, Hertenstein B, Radermacher J. Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure. *Eur J Haematol*. 2005 Jun;74(6):533-4.

Boesler B, Czock D, Keller F, Griesshammer M, Seufferlein T, Karges W, Rasche FM. Clinical course of haemodialysis patients with malignancies and dose-adjusted chemotherapy. *Nephrol Dial Transplant*. 2005 Jun;20(6):1187-91.

Datum: 23.04.07

Czock D, Keller F, Heringa M, Rasche FM. Raloxifene pharmacokinetics in males with normal and impaired renal function. *Br J Clin Pharmacol*. 2005 Apr;59(4):479-82.

Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. *Clin Pharmacokinet*. 2005;44(1):61-98. Review.

Aymanns C, Keller F. [Drug dosage in renal failure -- traps and aids] *Med Klin (Munich)*. 2004 Oct 15;99(10):613-24; quiz 625.

Heering P, Braun N, Mullejans R, Ivens K, Zauner I, Funfstuck R, Keller F, Kramer BK, Schollmeyer P, Risler T, Grabensee B; German Collaborative Glomerulonephritis Study Group. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. *Am J Kidney Dis*. 2004 Jan;43(1):10-8.

Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. *Clin Pharmacol Ther*. 2002 Aug;72(2):142-50.

Uhl A, Czock D, Boehm BO, Zellner D, Mertz A, Keller F. Pharmacokinetics and pharmacodynamics of methylprednisolone after one bolus dose compared with two dose fractions. *J Clin Pharm Ther*. 2002 Aug;27(4):281-7.

Keller F, Griesshammer M, Haussler U, Paulus W, Schwarz A. Pregnancy and renal failure: the case for application of dosage guidelines. *Drugs*. 2001;61(13):1901-20. Review.

Sturmer T, Erb A, Keller F, Gunther KP, Brenner H. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. *Am J Med*. 2001 Nov;111(7):521-7.

Czock D, Giehl M, Keller F. A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides. *Clin Pharmacokinet*. 2000 Apr;38(4):367-75.

Zellner D, Frankewitsch T, Keller F. Synthesis of pharmacokinetic parameters of vancomycin via bootstrap methods. *Int J Clin Pharmacol Ther*. 1998 Oct;36(10):554-60.

Zellner D, Zellner GE, Keller F. Dependence of vancomycin clearance on renal function via regression and bootstrap methods. *J Clin Pharm Ther*. 1998 Apr;23(2):107-13.

Keller F, Frankewitsch T, Zellner D, Simon S, Czock D, Giehl M. Standardized structure and modular design of a pharmacokinetic database. *Comput Methods Programs Biomed*. 1998 Feb;55(2):107-15.

Dr. J. Hubacek, Institute for Clinical and Experimental Medicine, Prague

Hubacek JA, Bohuslavova R, Skodova Z, Pitha J, Bobkova D, Poledne R.

Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change.

Clin Chem Lab Med. 2007;45(3):316-20.

Hubacek JA, Weichetova M, Bohuslavova R, Skodova Z, Stepan JJ, Adamkova V.

No associations between genetic polymorphisms of TGF-beta, PAI-1, and COL1A1, and bone mineral density in Caucasian females.

Endocr Regul. 2006 Dec;40(4):107-12.

Hubacek JA, Weichetova M, Bohuslavova R, Skodova Z, Adamkova V, Stepan JJ.

Genetic polymorphisms of TGF-beta, PAI-1, and COL1A-1, and determination of bone mineral density in Caucasian females.

Endocr Regul. 2006 Sep;40(3):77-81.

Riha H, Hubacek JA, Poledne R, Kellovsky P, Brezina A, Pirk J.

IL-10 and TNF-beta gene polymorphisms have no major influence on lactate levels after cardiac surgery.

Eur J Cardiothorac Surg. 2006 Jul;30(1):54-8. Epub 2006 May 24.

Datum: 23.04.07

Hubacek JA, Skodova Z, Adamkova V, Lanska V, Pitha J.
APOA5 variant Ser19Trp influences a decrease of the total cholesterol in a male 8 year cohort.
Clin Biochem. 2006 Feb;39(2):133-6. Epub 2005 Dec 28.

Hubacek JA, Bobkova D.
Role of cholesterol 7alpha-hydroxylase (CYP7A1) in nutrigenetics and pharmacogenetics of cholesterol lowering.
Mol Diagn Ther. 2006;10(2):93-100. Review.

Kadlecova M, Hojna S, Bohuslavova R, Hubacek JA, Zicha J, Kunes J.
Apolipoprotein A5 and hypertriglyceridemia in Prague hypertriglyceridemic rats.
Physiol Res. 2006;55(4):373-9. Epub 2005 Oct 17.

Hubacek JA, Skodova Z, Adamkova V, Lanska V, Poledne R.
Sex-specific effect of APOAV variant (Val153>Met) on plasma levels of high-density lipoprotein cholesterol.
Metabolism. 2005 Dec;54(12):1632-5.

Hubacek JA.
Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants.
Clin Chem Lab Med. 2005;43(9):897-902. Review.

Hubacek JA, Skodova Z, Lanska V, Stavek P, Adamkova V, Poledne R.
Apolipoprotein AV variants do not affect C-reactive protein levels in Caucasian males.
Physiol Res. 2005;54(6):687-9. Epub 2005 Apr 26.

Hubacek JA, Adamkova V, Skodova Z.
Rare variant of apolipoprotein E (Arg136 -->Ser) in two normolipidemic individuals.
Physiol Res. 2005;54(5):573-5. Epub 2005 Jan 10.

Viklicky O, Hubacek JA, Kvasnicka J, Matl I, Voska L, Skibova J, Teplan V, Vitko S.
Association of methylenetetrahydrofolate reductase T677 allele with early development of chronic allograft nephropathy.
Clin Biochem. 2004 Oct;37(10):919-24.

Hubacek JA, Kovar J, Skodova Z, Pit'ha J, Lanska V, Poledne R.
Genetic analysis of APOAV polymorphisms (T-1131/C, Ser19/Trp and Val153/Met): no effect on plasma remnant particles concentrations.
Clin Chim Acta. 2004 Oct;348(1-2):171-5.

Hubacek JA, Skodova Z, Adamkova V, Lanska V, Bobkova D, Poledne R. APOAV (T-1131>C) variant has no effect on mother's height in a large population study.
Lipids Health Dis. 2004 May 24;3:10.

Reiterova J, Miroslav M, Stekrova J, Kohoutova M, Tesar V, Kmentova D, Hubacek JA, Viklicky O.
The influence of G-protein beta3-subunit gene and endothelial nitric oxide synthase gene in exon 7 polymorphisms on progression of autosomal dominant polycystic kidney disease.
Ren Fail. 2004 Mar;26(2):119-25.

Hubacek JA, Skodova Z, Adamkova V, Lanska V, Poledne R.
The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction.
Clin Genet. 2004 Feb;65(2):126-30.

Kovar J, Suchanek P, Hubacek JA, Poledne R.
The A-204C polymorphism in the cholesterol 7alpha-hydroxylase (CYP7A1) gene determines the cholesterolemia responsiveness to a high-fat diet.
Physiol Res. 2004;53(5):565-8.

Hubacek JA, Berge KE, Stefkova J, Pitha J, Skodova Z, Lanska V, Poledne R.

Datum: 23.04.07

Polymorphisms in ABCG5 and ABCG8 transporters and plasma cholesterol levels.
Physiol Res. 2004;53(4):395-401.

Stefkova J, Poledne R, Hubacek JA.
ATP-binding cassette (ABC) transporters in human metabolism and diseases.
Physiol Res. 2004;53(3):235-43. Review.

Hubacek JA, Adamkova V, Ceska R, Poledne R, Horinek A, Vrablik M.
New variants in the apolipoprotein AV gene in individuals with extreme triglyceride levels.
Physiol Res. 2004;53(2):225-8.

Hubacek JA, Adamkova V, Skodova Z, Lanska V, Poledne R.
No relation between angiotensin-converting enzyme gene polymorphism and smoking dependence.
Scand J Clin Lab Invest. 2004;64(6):575-8.

Vrablik M, Horinek A, Ceska R, Adamkova V, Poledne R, Hubacek JA.
Ser19-->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people.
J Med Genet. 2003 Aug;40(8):e105. No abstract available.

Hubacek JA, Pitha J, Skodova Z, Poledne R, Lanska V, Waterworth DM, Humphries SE, Talmud PJ;
Czech MONICA Study.
Polymorphisms in CYP-7A1, not APOE, influence the change in plasma lipids in response to
population dietary change in an 8 year follow-up; results from the Czech MONICA study.
Clin Biochem. 2003 Jun;36(4):263-7.

Hubacek JA, Pitha J, Adamkova V, Skodova Z, Lanska V, Poledne R.
Apolipoprotein E and apolipoprotein CII polymorphisms in the Czech population: almost complete
linkage disequilibrium of the less frequent alleles of both polymorphisms.
Physiol Res. 2003;52(2):195-200.

Hubacek JA, Pitha J, Skodova Z, Adamkova V, Podrapska I, Schmitz G, Poledne
R.
Polymorphisms in the lipopolysaccharide-binding protein and bactericidal/permeability-increasing
protein in patients with myocardial infarction.
Clin Chem Lab Med. 2002 Nov;40(11):1097-100.

Cervenka L, Horacek V, Vaneckova I, Hubacek JA, Oliverio MI, Coffman TM, Navar LG.
Essential role of AT1A receptor in the development of 2K1C hypertension.
Hypertension. 2002 Nov;40(5):735-41.

Viklicky O, Hubacek JA, Vitko S, Heemann UW, Vasarhelyi B, Kohnle M, Teplan
V, Lacha J, Szabo AJ.
G-protein beta-3-subunit and eNOS gene polymorphism in transplant recipients with long-term renal
graft function.
Kidney Blood Press Res. 2002;25(4):245-9.
Hubacek JA, Pitha J, Skodova Z, Poledne R.
Rare variant of apolipoprotein E (Arg136-->Cys) in a subject with normal lipid values.
Physiol Res. 2002;51(1):107-8.

Hubacek JA, Pistulkova H, Skodova Z, Berg K, Poledne R.
Association between apolipoprotein B promoter haplotypes and cholesterol status.
Ann Clin Biochem. 2001 Jul;38(Pt 4):399-400.

Viklicky O, Hubacek JA, Pitha J, Teplan V, Heemann UW, Lacha J, Vitko S.
ACE gene polymorphism and long-term renal graft function.
Clin Biochem. 2001 Feb;34(1):87-90.

Lacha J, Hubacek JA, Viklicky O, Malek I, Hutchinson I, Vitko S.
TGF-beta1 gene polymorphism is a risk factor for renal dysfunction in heart transplant recipients.
Transplant Proc. 2001 Feb-Mar;33(1-2):1567-9. No abstract available.

Lacha J, Hubacek JA, Potmesil P, Viklicky O, Malek I, Vitko S.

Datum: 23.04.07

TGF-beta I gene polymorphism in heart transplant recipients--effect on renal function.
Ann Transplant. 2001;6(1):39-43.

Hubacek JA, Pitha J, Skodova Z, Adamkova V, Lanska V, Poledne R.
A possible role of apolipoprotein E polymorphism in predisposition to higher education.
Neuropsychobiology. 2001;43(3):200-3.

Hubacek JA, Waterworth DM, Pitha J, Humphries SE, Talmud PJ, Poledne R.
Polymorphisms in the lipoprotein lipase and hepatic lipase genes and plasma lipid values in the Czech population.
Physiol Res. 2001;50(4):345-51.

Hubacek JA, Lacha J.
Alternative method for diagnosis of two polymorphisms in the human transforming growth factor-beta1 by PCR-mediated double site-directed mutagenesis.
Clin Chim Acta. 2000 May;295(1-2):187-91.

Hubacek JA, Pitha J, Podrapska I, Sochman J, Adamkova V, Lanska V, Poledne R.
Insertion/deletion polymorphism in the angiotensin-converting enzyme gene in myocardial infarction survivors.
Med Sci Monit. 2000 May-Jun;6(3):503-6.

Hubacek JA, Pitha J, Stavek P, Schmitz G, Poledne R.
Variable expression of hypercholesterolemia in Apolipoprotein E2* (Arg136 --> Cys) heterozygotes.
Physiol Res. 2000;49(3):307-14.

Hubacek JA, Pistulkova H, Valenta Z, Poledne R.
(TTA)_n repeat polymorphism in the HMG-CoA reductase gene and cholesterolaemia.
Vasa. 1999 Aug;28(3):169-71.

Hubacek JA, Rothe G, Pit'ha J, Skodova Z, Stanek V, Poledne R, Schmitz G.
C(-260)-->T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction.
Circulation. 1999 Jun 29;99(25):3218-20. Erratum in: Circulation 1999 Dec 21-28;100(25):2550.

Hubacek JA, Poledne R.
The common cDNA and amino acid sequences of the CD14 (myeloid cell-specific leucine-rich glycoprotein) receptor.
Physiol Res. 1999;48(4):323-6.

Hubacek JA, Pistulkova H, Pisa Z, Valenta Z, Skodova Z, Poledne R.
Lack of an association between apolipoprotein B XbaI polymorphism and blood lipid parameters in childhood.
Physiol Res. 1998;47(2):89-93.